KURA Kura Oncology, Inc.

$13.15 +0.27%

Updated 16 d ago

Healthcare · Pharmaceutical Preparations

Kura Oncology, Inc. (KURA) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $1.2 billion. Shares last traded at $13.15, 5.3% below their 52-week high. Over the past year the stock is up 56.0%. Net profit margin is -384.3%, below the peer median of -8.9%. Revenue grew 25.2% year over year.

Market Cap

$1.2B

Shares Out

89.0M

EPS (TTM)

$-6.10

P/E Ratio

—

P/S Ratio

15.15

P/B Ratio

24.15

Dividend / Share

—

Dividend Yield

—

52-Week High

$13.89

52-Week Low

$7.36

Volume

90,861

Avg Vol (3m)

98,840.746

Performance

-0.19%

+42.86%

+50.11%

+54.89%

YTD

+27.18%

+55.99%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

65.33

SMA (50)

$11.05

SMA (200)

$9.80

Price vs SMA50

+18.96%

Price vs SMA200

+34.18%

ATR (14)

$0.63

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$77M

Net Income

$-297M

Gross Margin

—

Operating Margin

-411.9%

Net Margin

-384.3%

Return on Equity

-612.8%

Return on Assets

-50.5%

Current Ratio

4.73

Debt / Equity

0.12

Revenue Growth (YoY)

+25.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$-1.60	2026-08-12
Q1 2026	$-0.83	2026-05-12
FY 2025	$-3.18	2026-03-05
Q3 2025	$-2.26	2025-11-04
Q2 2026	$-1.41	2026-08-12
Q1 2026	$-0.66	2026-05-12

Full earnings history →

Pharmaceutical Preparations peers

KURA vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated 16 d ago

P/S vs peers

15.15 / 11.11 med

+36% premium

Net margin vs peers

-384.3% / -8.9% med

below median

1–14 of 14


LLY	Lilly (Eli)	$1.09T	40.86	13.70	33.5%	-0.02%
JNJ	Johnson & Johnson	$670.6B	31.88	6.85	21.5%	+1.04%
ONC	Beone Medicines Ltd.	$535.9B	817.25	87.43	10.7%	+0.23%
ABBV	AbbVie	$459.8B	72.87	7.14	9.8%	-0.57%
MRK	Merck	$375.8B	118.44	5.65	4.8%	+0.44%
ABT	Abbott Laboratories	$189.5B	30.20	4.20	13.9%	-1.50%
PFE	Pfizer	$164.2B	37.91	2.58	6.8%	-0.76%
VRTX	Vertex Pharmaceuticals	$141.5B	32.11	11.24	35.0%	+0.24%
BMY	Bristol Myers Squibb	$139.1B	14.98	2.83	18.9%	+0.62%
REGN	Regeneron Pharmaceuticals	$87.2B	20.15	5.61	27.9%	-1.02%
TEVA	Teva Pharmaceutical Industries Ltd	$42.6B	60.41	2.46	4.1%	-2.32%
ALNY	Alnylam Pharmaceuticals	$35.4B	43.77	9.52	21.8%	-1.10%
ZTS	Zoetis	$31.5B	12.05	3.31	27.5%	+0.16%
RPRX	Royalty Pharma Plc	$28.2B	34.56	11.11	32.1%	+1.24%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.